title: Interventions for the treatment of borderline ovarian tumours.
abstract: BACKGROUND
  The safety of conservative surgery and the benefit of additional interventions after surgery for borderline ovarian tumours are unknown.
  
  
  OBJECTIVE
  To evaluate the benefits and harm of different treatment modalities offered for borderline ovarian tumours.
  
  
  METHODS
  We searched the Cochrane Gynaecological Cancer Group Trials Register to 2009, Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2008, Issue 4), MEDLINE and EMBASE to 2009. We also searched registers of clinical trials, abstracts of scientific meetings, reference lists of included studies.
  
  
  METHODS
  Randomised controlled trials (RCTs) that compared different interventions in adult women diagnosed with borderline ovarian tumours of any histological variant.
  
  
  METHODS
  Two review authors independently abstracted data and assessed risk of bias.
  
  
  RESULTS
  We identified seven RCTs that enrolled 372 women. We could not pool results of trials as the treatment comparisons differed.Six RCTs (n = 340) conducted over 15 years ago, evaluated adjuvant therapy (chemotherapy, pelvic external irradiation or intra-peritoneal radioactive isotope therapy) after radical surgery; over 87% of participants had Stage I tumours. Most participants were followed up for over 10 years. Overall and recurrence-free survival were similar between both arms of these trials, except that one trial (n = 66) showed a significantly lower survival (P = 0.03) in women who received chemotherapy (thio-TEPA). Adverse effects of treatment were incompletely reported and all six trials were at high risk of bias.One further trial (n = 32) that recruited participants with bilateral serous tumours who were wishing fertility preservation, revealed a significantly increased chance of pregnancy (hazard ratio (HR) = 3.3, 95% CI 1.4 to 8.0) but non-significantly earlier disease recurrence (HR = 1.5, 95% CI 0.6 to 3.8) in the women who had ultra-conservative surgery (bilateral cystectomy) than in those who had conservative surgery (cystectomy and contralateral oophorectomy). This trial was at low risk of bias.Quality of life (QoL) was not documented in any included trial. We did not find any trials that compared radical with conservative surgery or laparoscopy with laparotomy.
  
  
  CONCLUSIONS
  We did not find evidence to support the use of any specific type of adjuvant therapy for borderline ovarian tumours. RCTs evaluating the benefit of adjuvant therapy with optimally dosed chemotherapy and newer targeted drugs are necessary, particularly for advanced borderline ovarian tumours. The low mortality from borderline ovarian tumours should make recurrence-free survival, time to recurrence and morbidity important end points in such trials.Bilateral cystectomy may be offered to women with bilateral borderline ovarian tumours diagnosed intra-operatively who are wishing to preserve their fertility. Similarly, women who had RCTs comparing radical with conservative surgery and comparing laparoscopy with laparotomy are needed.
authors.affiliation: Edinburgh Cancer Centre, Western General Hospital, Crewe Road, Edinburgh, Scotland, UK, EH4 2XU.
authors.forename: Olusola
authors.initials: O
authors.lastname: Faluyi
authors.forename: Melanie
authors.initials: M
authors.lastname: Mackean
authors.forename: Charlie
authors.initials: C
authors.lastname: Gourley
authors.forename: Andrew
authors.initials: A
authors.lastname: Bryant
authors.forename: Heather O
authors.initials: HO
authors.lastname: Dickinson
mesh_terms: D000328:Adult; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D011247:Pregnancy; D011788:Quality of Life; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic
references.citation: Cancer. 1992 Feb 1;69(3):741-9
references.pmid: 1730124
references.citation: J Natl Cancer Inst. 2003 Jan 15;95(2):113-25
references.pmid: 12529344
references.citation: J Clin Oncol. 2000 Jan;18(1):106-15
references.pmid: 10623700
references.citation: J Natl Cancer Inst. 2003 Jan 15;95(2):125-32
references.pmid: 12529345
references.citation: Lancet. 2002 Aug 17;360(9332):505-15
references.pmid: 12241653
references.citation: Gynecol Oncol. 2006 May;101(2):255-60
references.pmid: 16307793
references.citation: Fertil Steril. 2001 Jan;75(1):92-6
references.pmid: 11163822
references.citation: Stat Med. 1998 Dec 30;17(24):2815-34
references.pmid: 9921604
references.citation: Obstet Gynecol. 1982 Jan;59(1):93-6
references.pmid: 7078855
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: J Natl Cancer Inst. 2008 Mar 19;100(6):399-406
references.pmid: 18334710
references.citation: Hum Reprod. 2007 Feb;22(2):578-85
references.pmid: 17050549
references.citation: Cancer. 1986 Nov 1;58(9):2052-65
references.pmid: 3756820
references.citation: Int J Gynecol Pathol. 1993 Apr;12(2):120-7
references.pmid: 8463035
references.citation: Am J Obstet Gynecol. 1977 Jul 15;128(6):617-25
references.pmid: 406788
references.citation: Lancet Oncol. 2009 Apr;10(4):327-40
references.pmid: 19282241
references.citation: BMJ. 2010 Mar 23;340:c332
references.pmid: 20332509
references.citation: Eur J Obstet Gynecol Reprod Biol. 2007 Nov;135(1):3-7
references.pmid: 17983919
references.citation: Obstet Gynecol. 2002 Jan;99(1):3-10
references.pmid: 11777502
references.citation: Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):201-7
references.pmid: 12909234
references.citation: J Clin Oncol. 2007 Jul 10;25(20):2928-37
references.pmid: 17617524
references.citation: Cancer. 2002 Dec 1;95(11):2380-9
references.pmid: 12436446
references.citation: Hum Reprod. 2010 Aug;25(8):1966-72
references.pmid: 20573679
references.citation: Mod Pathol. 2005 Feb;18 Suppl 2:S33-50
references.pmid: 15761465
references.citation: Gynecol Oncol. 1992 Nov;47(2):150-8
references.pmid: 1468692
references.citation: Cancer. 2003 May 15;97(10 Suppl):2631-42
references.pmid: 12733128
references.citation: Am J Surg Pathol. 2006 Nov;30(11):1367-71
references.pmid: 17063075
references.citation: Int J Gynecol Cancer. 2007 Mar-Apr;17(2):342-9
references.pmid: 17343573
references.citation: Curr Opin Obstet Gynecol. 2003 Feb;15(1):39-43
references.pmid: 12544500
references.citation: Br J Obstet Gynaecol. 1998 Nov;105(11):1136-47
references.pmid: 9853761
references.citation: Fertil Steril. 2005 Feb;83(2):284-90; quiz 525-6
references.pmid: 15705364
references.citation: Gynecol Oncol. 1993 Nov;51(2):236-43
references.pmid: 8276300
references.citation: Gynecol Oncol. 1991 Jun;41(3):230-3
references.pmid: 1869100
references.citation: J Clin Epidemiol. 1997 Jun;50(6):683-91
references.pmid: 9250266
references.citation: Br J Cancer. 1995 Aug;72(2):511-8
references.pmid: 7640241
references.citation: Gynecol Oncol. 1996 Feb;60(2):301-7
references.pmid: 8631556
references.citation: Adv Anat Pathol. 1999 Sep;6(5):247-74
references.pmid: 10472378
references.citation: Clin Cancer Res. 2007 Jun 15;13(12):3617-22
references.pmid: 17575226
references.citation: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references.pmid: 18287387
references.citation: Am J Obstet Gynecol. 1988 Nov;159(5):1088-94
references.pmid: 3189441
references.citation: Gynecol Oncol. 1990 Jul;38(1):90-8
references.pmid: 2162318
references.citation: N Engl J Med. 1990 Apr 12;322(15):1021-7
references.pmid: 2181310
references.citation: Acta Obstet Gynecol Scand. 2007;86(5):620-6
references.pmid: 17464594
references.citation: Cancer. 1996 Nov 15;78(10):2236-46
references.pmid: 8918420
references.citation: BMJ. 2003 Sep 6;327(7414):557-60
references.pmid: 12958120